Search for: "United States v. Buckman"
Results 81 - 100
of 124
Sorted by Relevance
|
Sort by Date
10 Feb 2012, 8:39 am
The court held otherwise, finding the claims to be “squarely within the parameters” of Buckman Co. v. [read post]
12 Apr 2012, 10:56 am
Buckman Co. v. [read post]
17 Dec 2014, 4:30 am
That doctrine comes into play when: (1) the federal plaintiff lost in state court; (2) the plaintiff complains of some injury from the state court judgment; (3) the state court judgment antedated the filing of the federal case; and (4) the plaintiff is inviting the federal court to reject the state court judgment. The plaintiffs appealed that decision to the Third Circuit, and that’s where we are today: Johnson v. [read post]
30 Jul 2009, 4:16 am
Under Buckman:[A] private litigant cannot sue a defendant for violating the FDCA. [read post]
3 Sep 2014, 9:00 am
United States ex rel. [read post]
22 Apr 2007, 12:57 am
In Buckman v. [read post]
12 Mar 2009, 7:00 am
The Court in Buckman Co. v. [read post]
16 Sep 2015, 7:05 am
Unilever United States, Inc. [read post]
12 Feb 2008, 8:29 am
" Buckman Co. v. [read post]
28 Oct 2015, 4:30 am
Garcia v. [read post]
12 Jun 2014, 10:46 am
Today the United States Supreme Court ruled in POM Wonderful v. [read post]
11 Jan 2012, 7:32 am
E.g., United States ex rel. [read post]
2 Jan 2014, 7:51 pm
Supreme Court, in United States v. [read post]
31 Jul 2008, 5:30 pm
Accord Phelps v. [read post]
26 Jun 2015, 12:00 pm
United States 14-1145Issue: Whether, under Holland v. [read post]
30 Apr 2014, 4:30 am
In Williams v. [read post]
18 Aug 2011, 11:10 pm
Sheppard, Mullin, Richter & Hampton, LLPDocket: 10-1339Issue(s): Whether under the implied preemption principles in Buckman Co. v. [read post]
24 Mar 2014, 6:34 am
Ct. at 1018; see also United States v. [read post]
5 Apr 2013, 1:01 pm
About the only good thing about Blockis its refusal to allow Parisian to testify directly that the defendant violated the FDCA, that being both an improper legal opinion and barred by Buckman Co. v. [read post]
27 Dec 2007, 7:09 am
It excludes evidence of comparative safety between drugs of the same class, fraud on the FDA (due to Buckman preemption), corporate ethics, and regulatory actions outside of the United States. [read post]
